RUNX1 and acute myeloid leukemia: AML samples with dominant negative or RUNX1-/- mutations (lacking the wild type allele) were much more responsive to glucocorticoids than AML sample wild type RUNX1 allele or with missense RUNX1 mutations, which are known to have no impact on RUNX1 function.